Remodeling “cold” tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona

• Published in: Acta pharmaceutica Sinica. B Vol. 12; no. 4; pp. 2057 - 2073
• Main Authors: He, Yang, Fang, Yuefei, Zhang, Meng, Zhao, Yuge, Tu, Bin, Shi, Mingjie, Muhitdinov, Bahtiyor, Asrorov, Akmal, Xu, Qin, Huang, Yongzhuo
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.04.2022; Elsevier
• Subjects: Angiogenesis; Epigenetic therapy; Immune checkpoint; JQ1; Liposome; Original; Panobinostat; Tumor immune microenvironment; Tumor-associated macrophage; Panobinostat; Angiogenesis; Immune checkpoint; Liposome; Tumor immune microenvironment; Epigenetic therapy; Tumor-associated macrophage; JQ1
• ISSN: 2211-3835; 2211-3843
• DOI: 10.1016/j.apsb.2021.09.022

There is a close connection between epigenetic regulation, cancer metabolism, and immunology. The combination of epigenetic therapy and immunotherapy provides a promising avenue for cancer management. As an epigenetic regulator of histone acetylation, panobinostat can induce histone acetylation and inhibit tumor cell proliferation, as well as regulate aerobic glycolysis and reprogram intratumoral immune cells. JQ1 is a BRD4 inhibitor that can suppress PD-L1 expression. Herein, we proposed a chemo-free, epigenetic-based combination therapy of panobinostat/JQ1 for metastatic colorectal cancer. A novel targeted binary-drug liposome was developed based on lactoferrin-mediated binding with the LRP-1 receptor. It was found that the tumor-targeted delivery was further enhanced by in situ formation of albumin corona. The lactoferrin modification and endogenous albumin adsorption contribute a dual-targeting effect on the receptors of both LRP-1 and SPARC that were overexpressed in tumor cells and immune cells (e.g., tumor-associated macrophages). The targeted liposomal therapy was effective to suppress the crosstalk between tumor metabolism and immune evasion via glycolysis inhibition and immune normalization. Consequently, lactic acid production was reduced and angiogenesis inhibited; TAM switched to an anti-tumor phenotype, and the anti-tumor function of the effector CD8+ T cells was reinforced. The strategy provides a potential method for remodeling the tumor immune microenvironment (TIME). The lactoferrin-modified and albumin-adsorbed liposome for targeting tumor microenvironment was designed for epigenetic-based combination therapy. This tumor-targeting liposome can activate anti-tumor immunity responses, inhibit aerobic glycolysis and angiogenesis, and restrict tumor growth and metastasis via epigenetic regulation. [Display omitted]